Med Life Sa · BVB:M
Med Life Sa — Q1 2025 Earnings Presentation
18 slides from Med Life Sa's earnings presentation, May 15, 2025
Slide 1: Q1 2025 Presentation
Q1 2025 Presentation 15 May 2025 www.medlife.ro www.medlife.ro
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 Q1 2025 Highlights • • Key messages Outlook 2 • Consolidated Statement of Profit and Loss Q1 2025 AGENDA • Consolidated Statement of Financial Position Financial Results • Consolidated Statement of Cash Flow 3 Q&A Session 3
Slide 4: Q1 2025 Highlights
Q1 2025 Highlights • Key Messages • Outlook 1
Slide 5: Key messages
Key messages The Group reported a consolidated pro-forma turnover of RON 779 million, reflecting a 20% increase compared to the same period last year. Revenue grew organically by 16%, with strong demand for medical services, both in preventive care and complex medical procedures. In terms of busines
Slide 6: Key messages
Key messages Strategic investments in the Group’s hospital and laboratory divisions We have made significant progress in innovation and medical technology. We strengthened our position in the field of robotic surgery by introducing the Rosa robot, dedicated to high-precision orthopedic procedures. A
Slide 7: Outlook
Outlook Strategic priorities • We are strengthening our position as technology-driven company in the private healthcare sector by integrating advanced solutions such as drones, surgical robots, artificial intelligence, and automation to meet patients' needs in the medium and long term; • We announce
Slide 8: Q1 2025 Financial Results
Q1 2025 Financial Results • Consolidated Statement of Profit and Loss • Pro-forma Figures • QoQ Evolution • Operational KPIs • OPEX Evolution • Consolidated Statement of Financial Position • Debt Position • Consolidated Statement of Cash Flow 2
Slide 9: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss 3M 2024 3M 2025 Pro-forma 3M 2025 % var. % var. IFRS IFRS adjusted Pro-forma Consolidated Pro-forma turnover Gross sales 646,621,900 777,633,321 20.3 % 1,088,835 778,722,156 20.4 % Net sales (less NHP) 646,621,900 777,633,321 20.3 % (55,433,451) 722,199,871
Slide 10: Pro-forma Figures
Pro-forma Figures Pro-forma Revenues Pro-forma EBITDA 777,633,321 722,199,871 113,068,455 116,117,595 1,088,835 -56,522,286 144,088 2,905,051 3m 2025 Acquisitions National Program 3m 2025 3m 2025 Acquisitions One-off expenses 3m 2025 IFRS Reclass Pro-forma IFRS Pro-forma From IFRS Revenues to Pro-fo
Slide 11: QoQ Evolution
QoQ Evolution 120 113.1 EBITDA evolution (RON m vs % margin) 105.1 19.0% 98.1 95.1 96.7 100 17.2% 17.0% 72.2 74.7 75.8 80 71.2 15.2% 63.5 67.2 62.4 14.3% 14.5% 14.5% 14.1% 13.8% 15.0% 60 13.5% 13.5% 14.4% 48.6 12.5% 12.2% 13.0% 40 20 10.3% 11.0% 0 9.0% Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '2
Slide 12: Operational KPIs
Operational KPIs 3m 2024 3m 2025 % Total Business line Category IFRS IFRS % var. IFRS Sales Under IFRS, the Revenues recorded a solid 20% increase, with 16% driven by organic Revenue 247,277,200 290,650,198 17.5% 37.4% Clinics Visits 1,064,126 1,190,616 11.9% growth. Most business lines maintained t
Slide 13: OPEX Evolution
OPEX Evolution % OPEX % Sales 3m ‘24 3m ‘25 3m ‘24 3m ‘25 3m ‘24 3m ‘25 % var. var. var. IFRS IFRS IFRS IFRS IFRS IFRS Consumable materials and repair materials 112,319,796 145,495,140 29.5% 18.5% 19.8% 1.3 p.p 17.4% 18.7% 1.3 p.p Commodities 57,659,250 57,118,839 -0.9% 9.5% 7.8% -1.7 p.p 8.9% 7.3%
Slide 14: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position December 31, 2024 March 31, 2025 % var. IFRS IFRS Non-current assets 2,357,408,397 2,401,830,889 1.9% Current assets, excluding Cash and cash equivalents 546,097,224 538,901,299 -1.3% Cash and cash equivalents 112,808,224 141,210,153 25.2% TOTAL ASSETS 3,
Slide 15: Debt Position
Debt Position December 31, 2024 March 31, 2025 % var. IFRS IFRS Leasing liabilities Current portion – Leasing 108,288,263 110,617,336 2.2% Long term portion - leasing 286,025,347 288,559,134 0.9% Stability of the Net Debt / Pro- TOTAL 394,313,610 399,176,470 1.2% forma EBITDA ratio with 3.72x at Fin
Slide 16: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow March 31, 2024 March 31, 2025 IFRS IFRS Net income before taxes 19,063,857 17,564,949 Adjustments for non-monetary items 80,668,958 97,005,319 Operating cash flow before working capital and other monetary changes 99,732,815 114,570,268 Cash used in working capital
Slide 17: Q&A session
Q&A session 3
Slide 18: Thank you!
MedLife Group 365, Calea Grivitei, Bucharest investors@medlife.ro Thank you!